PROVIDER*Update*





CONTRACTUAL | NOVEMBER 26, 2019 | UPDATE 19-929 | 3 PAGES

Injectable Medication HCPCS/DOFR Crosswalk Reference Table Update – 4th Quarter 2019

Approved updates are effective February 3, 2020

On October 15, 2019, the Pharmacy and Therapeutics (P&T) Committee approved updates to the Injectable Medication Healthcare Common Procedure Coding System (HCPCS)/Division of Financial Responsibility (DOFR) Crosswalk.

The approved updates are effective February 3, 2020, and listed on pages 2 and 3. Injectable medications are placed in DOFR categories that mirror the DOFR matrix categories in the Health Net* and CalViva Health *Provider Participation Agreement (PPA)*.

The update includes:

- Seven new injectable medications and DOFR categories.
- Updates and changes to 14 injectable medication procedure codes.
- One update to a category change.

Additional information

Relevant sections of the provider operations manuals have been revised to reflect the information contained in this update as applicable. Provider operations manuals are available electronically in the Provider Library, located on the provider website at provider.healthnet.com.

Providers are encouraged to access the provider portal online at provider.healthnet.com for real-time information, including eligibility verification, claims status, prior authorization status, plan summaries, and more.

If you have questions regarding the information contained in this update, contact CalViva Health at 1-888-893-1569.

THIS UPDATE APPLIES TO MEDI-CAL PROVIDERS:

- Physicians
- Participating Physician Groups • Hospitals
- Ancillary Providers

PROVIDER SERVICES 1-888-893-1569 www.healthnet.com

CalViva Health is a licensed health plan in California that provides services to Medi-Cal enrollees in Fresno, Kings and Madera counties. CalViva Health contracts with Health Net Community Solutions. Inc. to provide and arrange for network services. *Health Net Community Solutions, Inc. is a subsidiary of Health Net, LLC and Centene Corporation. Health Net is a registered service mark of Health Net, LLC. All other identified trademarks/service marks remain the property of their respective companies. All rights reserved. CONFIDENTIALITY NOTE FOR FAX TRANSNISSION: This facsimile may contain confidential information. The information is intended only for the use of the individual or entity named above. If you are not the intended recipient, or the person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution, or use of the information contained in this transmission is strictly PROHIBITED. If you have received this transmission in error, please notify the sender immediately by telephone or by return fax and destroy this transmission, along with any attachments. OTH036478EH00 (11/19)

Additions to injectable medication HCPCS/DOFR crosswalk

The following medications have been approved by the P&T Committee as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table. P&T Committee members include physicians and representatives from Health Net and CalViva Health participating physician groups (PPGs).

HCPCS	Drug name	Generic name	Primary category	Secondary category
Q5117	Kanjinti [™]	Trastuzumab-anns,10 mg	Therapeutic inj	Chemotherapy*
J3490	Vyleesi™	Bremelanotide for subcutaneous use	Self-injectable	
J2794	Ripererdal Consta [®]	Risperidone 0.5 mg, Injection	Therapeutic inj	
J7331	Sodium Hyaluronate 1%	Sodium hyaluronate 1% for intra-articular injection	Therapeutic inj	
Q5116	Trazimera™	Trastuzumab-qyyp, 10 mg	Therapeutic inj	Chemotherapy*
J7314	Yutiq [™]	Fluocinolone acetonide, intravitreal implant, 0.01 mg	Therapeutic inj	
Q5118	Zirabev™	Bevacizumab-bvzr,10 mg	Therapeutic inj	Chemotherapy*

Updates/changes to injectable medication procedure codes or medications

Updates to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table are based on changes or updates to HCPCS codes or changes in medication descriptions or availability. The following are changes to injectable medications currently listed in the crosswalk.

HCPCS	Drug name	Generic name	Comment
J3031	Ajovy®	Fremanezumab-VFR	Replaces J3590
J1943	Aristada Initio [®]	Aripiprazole lauroxil extended-release injectable suspension	Replaces C9035
J9269	Elzonris®	Tagraxofusp-erzs injection, for intravenous use	Replaces C9049
J9210	Gamifant®	Emapalumab-Izsg injection, for intravenous use	Replaces C9050
J9119	Libtayo®	Cemiplimab-Rwlc IV solution	Replaces C9044
J9313	Lumoxiti [™]	Moxetumomab pasudotox-tdfk for injection, for intravenous use	Replaces C9045
J0121	Nuzyra®	Omadacycline for injection	Replaces C9051
J0222	Onpattro [®]	Patisiran lipid complex injection, for intravenous use	Replaces C9036
J1096	Ozurdex®	Dexamethasone intravitreal implant	Replaces C9048
S1090	Propel®	Mometasone furoate sinus implant, 370 micrograms	Discontinued
J2798	Perseris [™]	Risperidone for extended-release injectable suspension	Replaces C9037

Updates, continued

HCPCS	Drug name	Generic name	Comment
J9204	Poteligeo®	Mogamulizumab-kpkc injection, for intravenous use	Replaces C9038
J1303	Ultomiris™	Ravulizumab-cwvz injection, for intravenous use	Replaces C9052
J0291	Zemdri™	Plazomicin injection, for intravenous use	Replaces C9039

Category changes to HCPCS crosswalk

Secondary category additions were made to the HCPCS crosswalk for the following existing injectable medication.

HCPCS	Drug name	Generic name	Primary category	Secondary category
J2786	Cinqair [®]	Reslizumab	Therapeutic inj	Home health/infusion

* HCPCS codes were taken from the Centers for Medicare & Medicaid Services (CMS) HCPCS website at www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Alpha-Numeric-HCPCS.html.